论文部分内容阅读
为了探讨激素替代治疗（ＨＲＴ）的心血管保护机制，观察了倍美力对绝经后妇女纤溶活性的影响。４８例绝经后妇女分为３组：安慰剂组１０例；单用倍美力组（Ｅ组）１７例；倍美力、孕激素合用组（Ｅ＋Ｐ组）２１例，并以２０例绝经前妇女作为对照。采用发色底物法测定了ＨＲＴ治疗前及治疗３个月后血浆组织纤溶酶原激活剂（ｔＰＡ）及其抑制因子（ＰＡＩ）活性。结果：绝经后妇女治疗前ＰＡＩ活性明显高于对照组（Ｐ＜０．０１）。安慰剂组治疗前后ｔＰＡ及ＰＡＩ均无显著性变化（Ｐ＞０．０５）。Ｅ及Ｅ＋Ｐ组治疗３个月后ＰＡＩ活性明显减低，ｔＰＡ活性明显升高（Ｐ＜０．０１），两组比较，治疗前后ｔＰＡ及ＰＡＩ活性均无显著性差异。认为ＨＲＴ可通过改善绝经后妇女纤溶活性保护心血管。
To investigate the mechanism of cardiovascular protection in hormone replacement therapy (HRT), the effect of Beomei on fibrinolytic activity in postmenopausal women was observed. Forty-eight postmenopausal women were divided into three groups: placebo group (n = 10), bemexhibium group (n = 17), bemeilide combined with progesterone group (n = 21) Women as a control. The chromogenic substrate method was used to determine the activity of plasminogen activator (tPA) and its inhibitor (PAI) in plasma before and 3 months after treatment. Results: The PAI activity in postmenopausal women was significantly higher than that in the control group (P <0.01). There was no significant difference in tPA and PAI before and after treatment in the placebo group (P> 0.05). At 3 months after treatment, the activity of PAI and the activity of tPA in E and E + P groups were significantly decreased (P <0.01). There was no significant difference in the activity of tPA and PAI between the two groups before and after treatment. HRT is thought to protect the cardiovascular system by improving fibrinolytic activity in postmenopausal women.